Health-related quality of lifeand cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial

A. Miller (Corresponding Author), J. Madalinska, T. Church, D. Crawford, M. Essink-Bot, V. Goel, H. de Koning, L. Määttänen, Tuomo Pentikäinen

Research output: Contribution to journalReview ArticleScientificpeer-review

16 Citations (Scopus)

Abstract

Decisions on policies for screening for prostate cancer require that information upon health-related quality of life (HRQL) and cost-effectiveness (CE) be available, as the lead time for some of the cases detected by screening will be very long and detriments in quality of life could have a major impact on the subjects remaining life-span. A framework within which both HRQL and cost-effectiveness of prostate cancer screening can be assessed is presented. Studies of both are ongoing in the European Randomised Study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial. Preliminary information confirms that it is important to study screened subjects and controls, and not to assume that inferences derived from study of prostate cancer outside screening trials can be extrapolated to the trials. However, it will require prolonged study to enable the overall effects on quality of life, and on cost-effectiveness to be determined. Such studies are ongoing for the two trials.
Original languageEnglish
Pages (from-to)2154-2160
Number of pages7
JournalEuropean Journal of Cancer
Volume37
Issue number17
DOIs
Publication statusPublished - 2001
MoE publication typeA2 Review article in a scientific journal

Fingerprint

Cost-Benefit Analysis
Ovary
Prostatic Neoplasms
Colon
Lung
Quality of Life
Health
Early Detection of Cancer

Cite this

Miller, A. ; Madalinska, J. ; Church, T. ; Crawford, D. ; Essink-Bot, M. ; Goel, V. ; de Koning, H. ; Määttänen, L. ; Pentikäinen, Tuomo. / Health-related quality of lifeand cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial. In: European Journal of Cancer. 2001 ; Vol. 37, No. 17. pp. 2154-2160.
@article{3c44e6922cd5454c967e42f102904c53,
title = "Health-related quality of lifeand cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial",
abstract = "Decisions on policies for screening for prostate cancer require that information upon health-related quality of life (HRQL) and cost-effectiveness (CE) be available, as the lead time for some of the cases detected by screening will be very long and detriments in quality of life could have a major impact on the subjects remaining life-span. A framework within which both HRQL and cost-effectiveness of prostate cancer screening can be assessed is presented. Studies of both are ongoing in the European Randomised Study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial. Preliminary information confirms that it is important to study screened subjects and controls, and not to assume that inferences derived from study of prostate cancer outside screening trials can be extrapolated to the trials. However, it will require prolonged study to enable the overall effects on quality of life, and on cost-effectiveness to be determined. Such studies are ongoing for the two trials.",
author = "A. Miller and J. Madalinska and T. Church and D. Crawford and M. Essink-Bot and V. Goel and {de Koning}, H. and L. M{\"a}{\"a}tt{\"a}nen and Tuomo Pentik{\"a}inen",
year = "2001",
doi = "10.1016/S0959-8049(01)00288-X",
language = "English",
volume = "37",
pages = "2154--2160",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier",
number = "17",

}

Miller, A, Madalinska, J, Church, T, Crawford, D, Essink-Bot, M, Goel, V, de Koning, H, Määttänen, L & Pentikäinen, T 2001, 'Health-related quality of lifeand cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial', European Journal of Cancer, vol. 37, no. 17, pp. 2154-2160. https://doi.org/10.1016/S0959-8049(01)00288-X

Health-related quality of lifeand cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial. / Miller, A. (Corresponding Author); Madalinska, J.; Church, T.; Crawford, D.; Essink-Bot, M.; Goel, V.; de Koning, H.; Määttänen, L.; Pentikäinen, Tuomo.

In: European Journal of Cancer, Vol. 37, No. 17, 2001, p. 2154-2160.

Research output: Contribution to journalReview ArticleScientificpeer-review

TY - JOUR

T1 - Health-related quality of lifeand cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial

AU - Miller, A.

AU - Madalinska, J.

AU - Church, T.

AU - Crawford, D.

AU - Essink-Bot, M.

AU - Goel, V.

AU - de Koning, H.

AU - Määttänen, L.

AU - Pentikäinen, Tuomo

PY - 2001

Y1 - 2001

N2 - Decisions on policies for screening for prostate cancer require that information upon health-related quality of life (HRQL) and cost-effectiveness (CE) be available, as the lead time for some of the cases detected by screening will be very long and detriments in quality of life could have a major impact on the subjects remaining life-span. A framework within which both HRQL and cost-effectiveness of prostate cancer screening can be assessed is presented. Studies of both are ongoing in the European Randomised Study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial. Preliminary information confirms that it is important to study screened subjects and controls, and not to assume that inferences derived from study of prostate cancer outside screening trials can be extrapolated to the trials. However, it will require prolonged study to enable the overall effects on quality of life, and on cost-effectiveness to be determined. Such studies are ongoing for the two trials.

AB - Decisions on policies for screening for prostate cancer require that information upon health-related quality of life (HRQL) and cost-effectiveness (CE) be available, as the lead time for some of the cases detected by screening will be very long and detriments in quality of life could have a major impact on the subjects remaining life-span. A framework within which both HRQL and cost-effectiveness of prostate cancer screening can be assessed is presented. Studies of both are ongoing in the European Randomised Study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial. Preliminary information confirms that it is important to study screened subjects and controls, and not to assume that inferences derived from study of prostate cancer outside screening trials can be extrapolated to the trials. However, it will require prolonged study to enable the overall effects on quality of life, and on cost-effectiveness to be determined. Such studies are ongoing for the two trials.

U2 - 10.1016/S0959-8049(01)00288-X

DO - 10.1016/S0959-8049(01)00288-X

M3 - Review Article

VL - 37

SP - 2154

EP - 2160

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 17

ER -